Published in Can J Urol on August 01, 2011
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Overview of fundamental study of pazopanib in cancer. Thorac Cancer (2014) 0.76
Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivo. Thorac Cancer (2015) 0.75
LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma. Br J Cancer (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol (1999) 8.46
Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst (2006) 6.58
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) 3.88
Systemic therapy for renal cell carcinoma. J Urol (2000) 2.89
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res (2010) 1.85
Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol (2009) 1.23
Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol (2001) 1.03
Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res (1999) 0.93
Targeted therapies for kidney cancer in urologic practice. Urol Oncol (2007) 0.93
No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. Eur J Cancer (2008) 0.90
Pazopanib trial data cannot support first-line use. Nat Rev Urol (2010) 0.81
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol (2009) 6.71
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol (2006) 3.88
Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol (2008) 3.46
Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol (2009) 3.38
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol (2011) 2.87
Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer (2008) 2.75
Academic ranking score: a publication-based reproducible metric of thought leadership in urology. Eur Urol (2011) 2.51
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology (2011) 2.20
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer (2011) 1.98
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78
Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol (2012) 1.78
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology (2010) 1.77
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol (2009) 1.70
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol (2004) 1.66
Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer (2008) 1.64
Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol (2012) 1.64
Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer (2009) 1.60
Enhancing renal masses with zero net growth during active surveillance. J Urol (2007) 1.59
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (2005) 1.57
Assessing performance trends in laparoscopic nephrectomy and nephron-sparing surgery for localized renal tumors. Urology (2012) 1.54
Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res (2006) 1.49
Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment. Urology (2013) 1.49
Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol (2002) 1.48
Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int (2014) 1.47
Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology (2011) 1.46
Robot-assisted partial nephrectomy: a large single-institutional experience. Urology (2010) 1.45
Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses. Can J Urol (2012) 1.45
Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol (2010) 1.44
Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int (2013) 1.41
Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care (2015) 1.41
Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma. J Urol (2012) 1.40
The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Can J Urol (2017) 1.39
How Hugh Hampton Young's treatment of President Woodrow Wilson's urinary retention and urosepsis affected the resolution of World War I. J Urol (2011) 1.38
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer (2004) 1.38
Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol (2008) 1.37
Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) (2009) 1.36
Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis (2006) 1.33
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int (2011) 1.31
Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol (2007) 1.28
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res (2002) 1.28
Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol (2004) 1.26
Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol (2006) 1.23
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res (2004) 1.22
Contemporary management of small renal masses. Eur Urol (2011) 1.19
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer (2007) 1.18
A review of contemporary data on surgically resected renal masses--benign or malignant? Urology (2013) 1.15
Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res (2003) 1.13
Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res (2008) 1.12
Predicting growth of solid renal masses under active surveillance. Urol Oncol (2008) 1.11
Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol (2013) 1.11
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer (2006) 1.10
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther (2012) 1.09
Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol (2003) 1.06
Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int (2008) 1.06
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res (2013) 1.06
Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw (2009) 1.05
Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol (2007) 1.05
Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol (2008) 1.05
Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int (2009) 1.05
Incidence and management of penetrating renal trauma in patients with multiorgan injury: extended experience at an inner city trauma center. J Urol (2004) 1.04
Serum amino acid levels as a biomarker for renal cell carcinoma. J Urol (2011) 1.02
Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer (2014) 1.02